Billings Clinic
Especially For:

Clinical Trials

Title   NSABP B43: Trastuzumab + Radiation or Radiation Alone for HER2+ DCIS
Description   A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
IRB Number   NSABP B43
Category   Breast Cancer
Inclusion/Notes   This is a '2-step randomization'. Step 1-HER2 testing on the tissue taken at the time of biopsy or surgery for HER2 positive or negative DCIS.
If negative, patients do not proceed to Step 2. If positive, patients are randomized (ie: coin toss) to receive either radiation therapy alone, or radiation + 2 doses of trastuzumab for the treatment of their DCIS.

There are numerous Inclusion and Exclusion criteria for this trial. Potential participants must meet all of the criteria to be eligible for the trial.
Status   Open
Start Date   12/28/2008
Principal Investigator (PI)   John Schallenkamp, MD
Contact Name   Joan Koch, RN
Contact Email
Phone   (406) 435-7481
Alternate Phone   (406) 435-7480
Fax   (406) 435-7489
Funding Source   NCI
Print This Page
Email to a Friend
Home | Contact | Site Map | Site Privacy Policy | Terms & Conditions | Patient Privacy Policy | Medical Records | Fast Command
2800 10th Ave. North | P.O. Box 37000 | Billings, Montana 59107 | 406.238.2500
© Copyright 2014 Billings Clinic. All Rights Reserved.